Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $24
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $24
ADMA Biologics Is Maintained at Strong Buy by Raymond James
ADMA Biologics Analyst Ratings
H.C. Wainwright Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $26
Key Takeaways From ADMA Biologics Analyst Ratings
H.C. Wainwright Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $18
Maintaining Buy Rating on ADMA Biologics Amid Auditor Resignation: Confidence in Fiscal Health and Compliance
ADMA Biologics (ADMA) Receives a Buy From Mizuho Securities
ADMA Biologics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $20 Price Target
Buy Rating Affirmed for ADMA Biologics Amid Strong Financial Performance and Promising R&D Prospects
ADMA Biologics Price Target Raised to $20.00/Share From $15.00 by Cantor Fitzgerald
ADMA Biologics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), ADMA Biologics (ADMA) and Veracyte (VCYT)
ADMA Biologics Analyst Ratings
ADMA Biologics Analyst Ratings
ADMA Biologics Analyst Ratings
Strong Financial Performance and Growth Prospects Affirm Buy Rating for ADMA Biologics